title: [Impact of center characteristics on outcome in ovarian cancer in Germany].
abstract: OBJECTIVE
  To evaluate the relationship between hospital characteristics and quality of care and outcome in ovarian cancer in Germany.
  
  
  METHODS
  This 2nd national survey in patients with histologically proven epithelial ovarian cancer diagnosed in the 3 (rd) quarter 2001 analyzed pattern of care in early (FIGO I-II A) and advanced (FIGO II B-IV) disease. We performed univariate and multivariate analysis of the role of hospital characteristics, like hospital-volume, participation in cooperative clinical studies, and hospital category (university vs central clinic vs. two lower categories in Germany) as prognostic factor.
  
  
  RESULTS
  165 hospitals documented 476 patients (= about one third of all patients diagnosed in Germany within one quarter). Patients treated in study-centres received more frequently standard care and showed superior survival (multivariate analysis including biologic prognostic factors: HR 1.71; 95 % CI 1.2-2.5; p = 0.007). 2-year-survival was 72 % and 64 % in study-centres and hospitals not participating in studies, respectively. Neither hospital category nor hospital-volume showed any significant impact on survival. Only analysis of surrogate parameters like pattern of care in early ovarian cancer revealed advantages related to hospital category. Furthermore, analysis of some surgical details revealed advantages for high-volume centres and hospital category.
  
  
  CONCLUSIONS
  Participation in clincal studies was the only transparent hospital characteristic with significant impact on prognosis of ovarian cancer. Study participation as criterion for quality of care should be included in counselling ovarian cancer patients and should help guiding selection of hospitals for primary therapy. All German hospitals with information about participation in cooperative clinical studies as well as in this quality assurance program are listed on the web.
authors.affiliation: Klinik für Gynäkologie and Gynäkologische Onkologie, HSK Wiesbaden, Germany. dubois.hsk-wiesbaden@uumail.de
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: J
authors.initials: J
authors.lastname: Rochon
authors.forename: C
authors.initials: C
authors.lastname: Lamparter
authors.forename: J
authors.initials: J
authors.lastname: Pfisterer
mesh_terms: D002986:Clinical Trials as Topic; D003376:Counseling; D005260:Female; D005858:Germany; D006801:Humans; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome